Prostate Cancer News

Updates in the Management of Prostate and Kidney Cancers (05/07/2008)
A report from the 2008 ASCO Genitourinary Cancers Symposium

Specific Gene Expression Predicts Risk for Prostate Cancer (05/05/2008)
Expression of the PTOV1 gene helps predict the likelihood of the development of prostate cancer among men with high-grade prostatic intraepithelial neoplasia (HG-PIN). These results were recently published in the journal Clinical Cancer Research.

Changes in Lifestyle May Improve Quality of Life for Prostate Cancer Survivors (05/05/2008)
A recent study conducted by the American Cancer Society reports that although few cancer survivors follow recommendations for lifestyle changes aimed to improve health and well-being, adhering to these guidelines may improve quality of life among prostate cancer survivors. Full details of the study were recently published in the Journal of Clinical Oncology.

GVAX® Promising for Recurrent Prostate Cancer (04/21/2008)
The immunotherapeutic vaccine GVAX® provides promising activity in patients with recurrent prostate cancer. These results were recently presented at the 2008 annual meeting of the American Association for Cancer Research.

Fluctuation in Weight May Influence Risk for Prostate Cancer (04/09/2008)
A large study conducted in Austria reveals that large weight gains or losses may influence an individual’s risk for developing certain types of cancer, including prostate cancer. Complete details of the study were published in the Annals of Oncology.

More...

Screening/Prevention

Specific Gene Expression Predicts Risk for Prostate Cancer (05/05/2008)
Expression of the PTOV1 gene helps predict the likelihood of the development of prostate cancer among men with high-grade prostatic intraepithelial neoplasia (HG-PIN). These results were recently published in the journal Clinical Cancer Research.

Fluctuation in Weight May Influence Risk for Prostate Cancer (04/09/2008)
A large study conducted in Austria reveals that large weight gains or losses may influence an individual’s risk for developing certain types of cancer, including prostate cancer. Complete details of the study were published in the Annals of Oncology.

Internet May Be Useful Tool for Education About Prostate Cancer (03/10/2008)
Public health Web sites may not be as useful to men concerned about prostate cancer as educational online presentations about the disease. This recent study was published in the Archives of Internal Medicine.

Testosterone Levels Not Associated with Risk of Prostate Cancer (01/30/2008)
According to an article recently published in the Journal of the National Cancer Institute, testosterone levels do not appear to be associated with risk of developing prostate cancer.

A Combination of Genetic Variants Found to be Associated with Prostate Cancer (01/25/2008)
A recent study published in the New England Journal of Medicine reveals that genetic variants located in five different chromosomal regions have been associated with prostate cancer.

More...

Early Stage I-II (A-B)

Updates in the Management of Prostate and Kidney Cancers (05/07/2008)
A report from the 2008 ASCO Genitourinary Cancers Symposium

Changes in Lifestyle May Improve Quality of Life for Prostate Cancer Survivors (05/05/2008)
A recent study conducted by the American Cancer Society reports that although few cancer survivors follow recommendations for lifestyle changes aimed to improve health and well-being, adhering to these guidelines may improve quality of life among prostate cancer survivors. Full details of the study were recently published in the Journal of Clinical Oncology.

Satisfaction with Treatment Outcome Reflects Quality of Life Among Prostate Cancer Survivors (03/28/2008)
A recent study indicates that prostate cancer treatment may be associated with changes in quality of life that impact satisfaction with treatment outcomes for both patients and their spouses or partners. These findings were published in the New England Journal of Medicine.

Differences in IMRT Radiation Doses May Complicate Study Results in Prostate Cancer (03/18/2008)
Differences between the prescribed dose of radiation in intensity modulated radiation therapy (IMRT) and the dose that’s actually delivered in prostate cancer treatment may make comparison studies difficult to interpret. These findings were reported in the Journal of the National Cancer Institute.

Androgen Suppression Improves Outcomes in Some Patients with Early Prostate Cancer (01/23/2008)
According to an article recently published in the Journal of the American Medical Association, androgen suppression therapy (AST), also referred to as androgen deprivation therapy, in addition to radiation therapy improved survival in some men with early prostate cancer. This improvement was limited to men with high-risk prostate cancer and those without other significant medical conditions.

More...

Locally Advanced Stage III (C)

Updates in the Management of Prostate and Kidney Cancers (05/07/2008)
A report from the 2008 ASCO Genitourinary Cancers Symposium

Changes in Lifestyle May Improve Quality of Life for Prostate Cancer Survivors (05/05/2008)
A recent study conducted by the American Cancer Society reports that although few cancer survivors follow recommendations for lifestyle changes aimed to improve health and well-being, adhering to these guidelines may improve quality of life among prostate cancer survivors. Full details of the study were recently published in the Journal of Clinical Oncology.

Satisfaction with Treatment Outcome Reflects Quality of Life Among Prostate Cancer Survivors (03/28/2008)
A recent study indicates that prostate cancer treatment may be associated with changes in quality of life that impact satisfaction with treatment outcomes for both patients and their spouses or partners. These findings were published in the New England Journal of Medicine.

Androgen Suppression Improves Outcomes in Some Patients with Early Prostate Cancer (01/23/2008)
According to an article recently published in the Journal of the American Medical Association, androgen suppression therapy (AST), also referred to as androgen deprivation therapy, in addition to radiation therapy improved survival in some men with early prostate cancer. This improvement was limited to men with high-risk prostate cancer and those without other significant medical conditions.

Androgen Deprivation Therapy Prior to Radiation Therapy Improves Outcomes in Locally Advanced Prostate Cancer (01/10/2008)
Compared with radiation therapy alone, a short course of androgen deprivation therapy before radiation therapy improves several outcomes among men with locally advanced prostate cancer. These results were published in the Journal of Clinical Oncology.

More...

Metastatic Stage IV (D)

Changes in Lifestyle May Improve Quality of Life for Prostate Cancer Survivors (05/05/2008)
A recent study conducted by the American Cancer Society reports that although few cancer survivors follow recommendations for lifestyle changes aimed to improve health and well-being, adhering to these guidelines may improve quality of life among prostate cancer survivors. Full details of the study were recently published in the Journal of Clinical Oncology.

Family Intervention Helps Spouses of Prostate Cancer Patients (11/15/2007)
According to the results of a study published in the journal Cancer, a family intervention that offered support and information to prostate cancer patients and their spouses provided important benefits, particularly to the spouses.

Exercise Reverses Bone Loss Caused by Androgen Deprivation for Prostate Cancer Patients (11/07/2007)
According to results presented at the 2007 annual meeting of the American Society of Therapeutic Radiation and Oncology (ASTRO), walking can reverse the effects of androgen deprivation therapy (ADT) on bone loss among men with prostate cancer.

Diagnosis and Management of Prostate Cancer: Highlights from the 2007 AUA Annual Meeting (10/15/2007)
At the 2007 Annual Meeting of the American Urological Association (AUA), presenters addressed many aspects of the disease from early detection to management of advanced stage. This review attempts to summarize a selection of interesting abstracts presented at the meeting and discuss the possible impact on current management of the disease. 

Prostate Cancer: Updates from the 2007 ASCO Prostate Cancer Symposium (10/15/2007)
The 2007 American Society of Clinical Oncology (ASCO) Prostate Cancer Symposium covered topics including risk factors, screening, prevention, prostate-specific antigen (PSA) as a marker, risk assessment, local treatments, biochemical failure, complications of therapy, and developmental therapeutics. 

More...

Refactory/Recurrent

Updates in the Management of Prostate and Kidney Cancers (05/07/2008)
A report from the 2008 ASCO Genitourinary Cancers Symposium

GVAX® Promising for Recurrent Prostate Cancer (04/21/2008)
The immunotherapeutic vaccine GVAX® provides promising activity in patients with recurrent prostate cancer. These results were recently presented at the 2008 annual meeting of the American Association for Cancer Research.

Intermittent Taxotere® Effective in Hormone-refractory Prostate Cancer (04/08/2008)
Intermittent administration of Taxotere® (docetaxel) appears to provide as much benefit, with fewer side effects, than continuous administration of Taxotere among patients with hormone-refractory prostate cancer. These results were recently presented at the 23^rd annual meeting of the European Association of Urology.

Family Intervention Helps Spouses of Prostate Cancer Patients (11/15/2007)
According to the results of a study published in the journal Cancer, a family intervention that offered support and information to prostate cancer patients and their spouses provided important benefits, particularly to the spouses.

Addition of Emcyt® Improves Survival in Prostate Cancer (10/19/2007)
According to an early online publication in The Lancet, the addition of the chemotherapy agent Emcyt® (estramustine) improves survival of patients with hormone refractory prostate cancer.

More...